In Simple Terms
Instead of going after the proteins that build up in the brain, ImmunoBrain is testing a drug that briefly activates the body’s defenses. The hope is that this will calm harmful inflammation and help protect brain cells. An early study found encouraging changes in some measurements, but it did not show that people’s memory improved or that the disease slowed down. A larger, longer study is needed.
From Protein Buildup to the Brain–Immune Connection
For years, much of Alzheimer’s research has focused on the buildup of proteins such as beta-amyloid and tau, and on ways to remove them or prevent them from forming. But protein buildup alone may not explain everything that happens after symptoms begin. Michal Schwartz, co-founder and chief scientific officer of ImmunoBrain, says Alzheimer’s can remain symptom-free for 10 to 20 years. As the disease progresses, another factor may come into play alongside the accumulating proteins: inflammation in the brain.
That does not mean inflammation starts the disease, Schwartz says, but it may help drive it forward. Early on, the brain’s resident immune cells—called microglia—can help protect neurons and limit damage. How well this response works depends in part on support from the immune system outside the brain. As people age, that peripheral immune support may weaken. Under some conditions, microglia can also shift into a state that fuels inflammation and harms the environment around neurons.
The treatment is based on the idea that brain health is linked to the state of the immune system throughout the body. A person’s age alone does not necessarily tell us how much the brain’s ability to function has declined; changes in the immune system may help determine how much protection neurons receive. So, rather than targeting a particular brain protein, this approach acts on an immune control point outside the brain. The aim is to interrupt a cycle in which weakening immune support and rising inflammation may reinforce each other.
An Antibody That Briefly Releases the Immune Brake
ImmunoBrain’s lead drug candidate is a monoclonal antibody called IBC-Ab002. It targets PD-L1, a protein involved in an immune pathway known as the PD-1/PD-L1 axis. This pathway helps restrain immune-cell activity. Temporarily blocking it may trigger a limited immune response that, according to the treatment’s hypothesis, directs repair-related cells from the blood toward the brain.
The company aims to make this interruption brief and intermittent, rather than keeping the immune system activated continuously. Schwartz’s proposed mechanism is that the treatment may encourage immune-derived monocytes, along with regulatory T cells that help control immune responses, to move toward the brain. These cells might help clear some aged microglia, reduce inflammation, and create a more supportive environment for neurons and synapses that are impaired but have not completely lost their ability to recover.
The antibody was also designed with features intended to reduce unwanted immune effects. It binds strongly to PD-L1, while modifications reduce activity in the antibody’s Fc region. The goal is to avoid antibody-dependent cell killing or the activation of complement against the cells it binds to. The antibody’s binding to the FcRn receptor has also been reduced. These precautions matter because the proposed treatment alters immune regulation in a chronic disease. The goal is not simply to produce a strong response, but to keep that response controlled, limited, and temporary.
This strategy differs from drugs that directly attack amyloid plaques or tau aggregates. It does not show that immune-based treatment can replace those approaches. Instead, it offers another possible way to intervene: supporting the immune system outside the brain may influence the inflammation that accompanies disease progression, even if the drug is not designed to remove accumulated proteins directly.
What Did the First Human Trial Find?
ImmunoBrain presented results from its first-in-human Phase Ib study at the 2026 Alzheimer’s Association International Conference in London, held from July 12 to 15. The results were also published in Nature Medicine. The study included 40 people with early-stage Alzheimer’s disease, divided into five groups to test increasing doses ranging from 1 to 30 milligrams per kilogram of body weight. Participants received four doses, given three months apart, and were then followed for one year.
The main purpose of the Phase Ib trial was to assess safety and tolerability—not to prove that the drug improves memory or slows the loss of cognitive abilities. The results should therefore be seen as an initial test of whether the treatment can be given and whether it produces signals worth investigating further. The drug’s half-life was about four days across all dose groups. The study recorded no cases of brain bleeding or amyloid-related imaging abnormalities, known as ARIA, which are among the effects monitored when evaluating some Alzheimer’s treatments.
In analyses of cerebrospinal fluid at week 48, the highest-dose group, which received 30 milligrams per kilogram, showed decreases in three measures compared with the pooled placebo group. Neurogranin, a marker associated with synapse health, fell by 23.1%. Total tau fell by 12.4%, and tau phosphorylated at position 181 fell by 11.0%. Individual responses showed some consistency across these three measures among participants who received the treatment.
The presynaptic marker VAMP2 also moved in a direction similar to neurogranin, and the two changes were strongly correlated across individuals. Schwartz described these signals as encouraging and highlighted neurogranin because of its links to Alzheimer’s disease and cognitive performance. But she emphasized that the number of participants was small and follow-up was limited, so the findings cannot be considered statistically significant or proof of clinical benefit. A change in a biological marker is not the same as a noticeable improvement in memory or in someone’s ability to manage daily activities.
Why Is the Immune Hypothesis Drawing Attention?
The approach builds on earlier research by Schwartz’s lab at the Weizmann Institute of Science in Rehovot, Israel. Her work has shown that the brain is not completely isolated from the immune system and depends on ongoing communication with it for protection, maintenance, and repair. In September, another paper published in Nature Neuroscience examined the production of bone-marrow-derived monocytes and their recruitment to the brain, both in a mouse model and in people with Alzheimer’s disease. The findings suggested that this process, which may contribute to a protective response, is disrupted in the disease.
That study focused on the bone marrow, where many immune cells are produced. Schwartz explained that the disruption was associated with persistently elevated type I interferon signals. Type I interferon normally helps the body respond to infection and inflammation, but if the signal stays active for too long, it may have the opposite effect: instead of protecting the body, it can interfere with the production of immune cells in the bone marrow. The researchers observed aspects of this disruption in both mice and humans, adding to the possibility that Alzheimer’s progression is shaped by processes beyond the brain itself.
The findings also point to the complicated relationship between infection and disease. Schwartz’s view is that in some cases, harm may be linked less to the virus itself than to an immune response that fails to switch off properly after a viral encounter. Her team previously published a 2014 study in Science linking brain aging in humans and mice to type I interferon signals. This body of work does not prove that any single factor explains Alzheimer’s disease. It does, however, provide a biological basis for the idea that disruptions in peripheral immunity and inflammation may interact with changes taking place in the brain.
Looking for Alternatives—and Recognizing the Limits of Early Evidence
ImmunoBrain’s effort comes in a field where effective treatments have been difficult to develop. A widely cited estimate from Cleveland Clinic says that 99.6% of Alzheimer’s drug candidates have failed. A 2022 analysis estimated that the failure rate among candidates that reached Phase II or Phase III trials was about 98%. These figures do not mean an immune-based approach will succeed. They do help explain why researchers are exploring different mechanisms, especially when promising laboratory findings or changes in biological markers do not translate into clear benefits for patients.
Francis Collins, director of the US National Institutes of Health from 2009 to 2021, is among those interested in this line of research and has joined ImmunoBrain’s board. Collins believes that human genetics research has pointed to the importance of pathways involving microglia and innate immunity, areas that, in his view, have received less therapeutic attention than the amyloid, tau, and lipid hypotheses. His appointment brings additional attention to the company’s work, but it is not evidence that the treatment works. That judgment still depends on the results of well-controlled clinical trials.
The company plans to move on to a Phase IIb trial. It has submitted filings to the US Food and Drug Administration and is working to raise the necessary funding. The proposed study is expected to follow participants for two years and use an ambitious clinical endpoint. That shift is important: the next trial needs to test whether the drug changes the course of symptoms or helps preserve cognitive function, rather than measuring only changes in fluid-based markers. It will also need enough participants and a rigorous design to distinguish treatment effects from natural changes and participants’ expectations.
For now, the Phase Ib findings are an early signal, not an announcement of a proven treatment. The declines in biological markers merit further study, and the absence of brain bleeding and ARIA in this small group is useful early safety information. But 40 participants are not enough to establish the benefits and risks across a broader population. Nor does a change in these markers guarantee that patients will feel better or experience a slower decline.
The Bottom Line
ImmunoBrain is pursuing a different approach to Alzheimer’s: briefly and carefully activating part of the immune system outside the brain, in hopes of improving communication between the body and brain and limiting inflammation that may worsen neurological damage. In a first human study involving 40 people, researchers observed encouraging changes in markers associated with neurons and synapses, with no brain bleeding or ARIA reported. But the trial was designed mainly to assess safety and tolerability, and it did not establish that the drug works. A planned Phase IIb study, with two years of follow-up and a clinical endpoint, will test whether this idea can move beyond changes in laboratory measures to deliver a real benefit to patients.